Literature DB >> 24078895

β -Lactamase-Producing Multidrug-Resistant Bacterial Pathogens from Tracheal Aspirates of Intensive Care Unit Patients at National Institute of Neurological and Allied Sciences, Nepal.

Santosh Khanal1, Dev Raj Joshi, Dwij Raj Bhatta, Upendra Devkota, Bharat Mani Pokhrel.   

Abstract

The widespread use of tracheal intubation and mechanical ventilation to support the critically ill patients increases the risk of development of tracheobronchitis and bronchopneumonia. This cross-sectional study was conducted with an aim to isolate and identify bacterial pathogens from tracheal aspirates producing extended-spectrum β -lactamase (ESBL), AmpC β -lactamase, and metallo- β -lactamase (MBL) from August 2011 to April 2012 at National Institute of Neurological and Allied Sciences (NINAS), Kathmandu, Nepal. ESBL was detected by combined disk assay using cefotaxime and cefotaxime with clavulanate, AmpC β -lactamase by inhibitor-based method using cefoxitin and phenylboronic acid, and MBL by Imipenem-EDTA combined disk method. 167 bacterial strains were isolated from 187 samples and majority of them were Acinetobacter spp. followed by Klebsiella pneumoniae with 32.9% and 25.1%, respectively. 68.8% of isolates were multidrug resistant (MDR) and Acinetobacter spp. constituted 85.4%. ESBL, AmpC β -lactamase, and MBL were detected in 35 (25%), 51 (37.2%), and 11 (36.7%) isolates, respectively. Pseudomonas spp. (42.8%) were the predominant ESBL producer while Acinetobacter spp. were the major AmpC β -lactamase producer (43.1%) and MBL producer (54.5%).

Entities:  

Year:  2013        PMID: 24078895      PMCID: PMC3775398          DOI: 10.1155/2013/847569

Source DB:  PubMed          Journal:  ISRN Microbiol


1. Introduction

Tracheostomy is a surgical procedure that creates an opening directly into the trachea to ventilate and aspirate the patient in critical care setting [1]. The incidence of ventilator-associated pneumonia (VAP) ranges from 10 to 25% of all intensive care unit (ICU) patients resulting in high mortality rate of 22–71%, which is 6–21 times higher in intubated patients [2]. The tracheostomized patients are colonized or infected with bacteria either endogenously or exogenously. Exogenous bacteria include Pseudomonas spp., Acinetobacter spp., methicillin-resistant Staphylococcus aureus (MRSA), and members of Enterobacteriaceae and endogenous bacteria include Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. These bacteria are usually resistant to multiple antibiotics and cause either tracheobronchitis or bronchopneumonia [3]. Risk factors for colonization or infection with multidrug-resistant bacterial species include prolonged length of hospital stay, exposure to an ICU, receipt of mechanical ventilation, colonization pressure, exposure to broad-spectrum antimicrobial agents, recent surgery, invasive procedures, and underlying severity of illness [4, 5]. β-Lactamases are the commonest cause of bacterial resistance to β-lactam antimicrobial agents, which are used in the treatment of various serious infections. With the increased use of antimicrobial agents, bacteria responded with a variety of new β-lactamases including extended-spectrum β-lactamases, plasmid-mediated AmpC β-lactamases and metallo-β-lactamases [6]. Infections caused by multidrug-resistant bacteria expressing β-lactamases pose serious challenges to clinicians because these bacteria are resistant to a broad range of β-lactams, including third-generation cephalosporins, and nosocomial infections caused by these organisms complicate therapy and limit treatment options [6, 7]. The emergence and spread of antimicrobial resistance due to the production of β-lactamases as a major problem have drawn attention to a need for better diagnostic techniques and newer drugs to allow more specific therapy. Therefore, the characterization and antibiotic susceptibility pattern of β-lactamase-producing organisms can lead to successful infection control, involving antimicrobial stewardship and public health interventions aimed at controlling the emergence of such life-threatening multidrug-resistant bacteria. Hence, this study was undertaken to detect the bacterial pathogens and determine the antimicrobial resistance pattern of clinically relevant bacteria producing extended-spectrum β-lactamase, AmpC β-lactamase, and metallo-β-lactamase from tracheal aspirate of patients admitted to ICU.

2. Materials and Methods

This cross-sectional study was conducted at National Institute of Neurological and Allied Sciences, Bansbari, Kathmandu, Nepal, from August 2011 to April 2012. A total of 187 tracheal aspirate samples were included in the study.

2.1. Specimen Collection

The samples were collected in mucus trapper by applying negative pressure through automated machine by experienced physician and samples were immediately transported to the laboratory.

2.2. Culture of the Specimen

The specimens were inoculated on blood agar, MacConkey agar, and chocolate agar plates. In the chocolate agar plate, a 5 μg optochin disc and a 10 U bacitracin disc were added to screen out S. pneumoniae and H. influenzae, respectively, and the plates were incubated at 37°C overnight in candle jar, whereas, the MacConkey and blood agar plates were incubated under aerobic condition [8].

2.3. Identification and Antibiotic Susceptibility Test

The isolates were identified on the basis of colony characterization, staining, and biochemical tests such as oxidase, catalase, sulfide indole motility, citrate, urea hydrolysis, triple sugar iron agar test, and coagulase tests [8]. Antibiotic sensitivity test was performed using the Kirby-Bauer disk diffusion method and sensitivity results were interpreted according to CLSI guidelines [9]. Multidrug resistance was defined as resistance to three or more of the antimicrobial agents belonging to different structural classes [10].

2.4. Test for ESBL, AmpC β-Lactamase, and MBL Production

ESBL was detected by combined disk assay using cefotaxime (30 μg) and cefotaxime (30 μg) with clavulanate (10 μg) [9], AmpC β-lactamase by inhibitor-based method using cefoxitin (30 μg) and cefoxitin (30 μg) with phenylboronic acid (20 μL) [11], and MBL by combined disk assay using Imipenem (10 μg) and Imipenem (10 μg) with 100 mM EDTA (10 μL) [12].

3. Results

Out of 187 tracheal aspirate samples, 138 males and 49 females, 146 (78.1%) samples showed significant growth with 21 polymicrobial growth. 167 bacterial strains were identified and among them, 115 (68.8%) were multidrug resistant. Among 167 isolates, Gram-negative bacteria constituted 154 (92.2%) of the total isolates, among which 108 (70.1%) were MDR. Among Gram-negatives, Acinetobacter spp. were the most frequently isolated species with 55 (32.9%) isolates and among them, 47 (85.4%) were found to be MDR-strains. Gram-positive organisms constituted 13 (7.8%) of the total isolates and 7 (53.8%) of them were MDR. Staphylococcus aureus constituted 12 isolates and 6 (50%) of these were MDR. The results are shown in Table 1.
Table 1

Pattern of microbial isolates from tracheal aspirate of ICU patients.

OrganismsFrequencyMDR (%)
Gram-negative bacteria 154 108 (70.1)
 Acinetobacter spp.5547 (85.4)
 K. pneumoniae 4231 (73.8)
 Pseudomonas spp.3719 (51.3)
 E. coli 126 (50)
 Enterobacter spp.32 (66.7)
 K. oxytoca 22 (100)
 Citrobacter freundii 20
 Proteus vulgaris 11 (100)
Gram-positive bacteria 13 7 (53.8)
 S. aureus 126 (50)
 S. pneumoniae 11 (100)
Total 167 115 (68.8)
Acinetobacter spp. showed high rate of resistance to cefepime (96.4%), cotrimoxazole (96.4%), cefoxitin (94.5%), cefotaxime (87.3%), gentamicin (83.6%), and ciprofloxacin (80%). Similarly, high rate of resistance was observed among K. pneumoniae and Pseudomonas spp. to cotrimoxazole, cefoxitin, cefotaxime, cefepime, and ciprofloxacin. The results are shown in Table 2.
Table 2

Antibiotic resistance rates (%) for predominant Gram-negative bacilli recovered from tracheal aspirate of ICU patients.

Antibiotics Acinetobacter spp. (N = 55) K. pneumoniae (N = 42) Pseudomonas spp. (N = 37) E. coli (N = 12)
Amikacin78.254.840.58.3
AmpicillinNT100NT100
CarbenicillinNTNT43.2NT
Cefepime96.483.378.466.7
Cefotaxime87.378.683.858.3
Cefoxitin94.58189.266.7
Ciprofloxacin8064.351.466.7
Cotrimoxazole96.485.786.583.3
ErythromycinNTNTNT25
Gentamicin83.66943.225
Imipenem23.69.516.20
Ofloxacin8064.351.466.7
Piperacillin-tazobactam69.157.129.7NT
Polymyxin B000NT

*NT: not tested.

Staphylococcus aureus showed high rate of resistance to ampicillin (83.3%), cotrimoxazole (50%), erythromycin (41.7%), cloxacillin (33.3%), and ciprofloxacin (33.3%). The results are shown in Table 3.
Table 3

Antibiotic resistance rates (%) for Gram-positive cocci recovered from tracheal aspirate of ICU patients.

Antibiotics S. aureus (N = 12) S. pneumoniae (N = 1)
AmikacinNT100
Ampicillin83.3100
Cefoxitin33.3100
CefotaximeNT100
Cloxacillin33.3NT
Ciprofloxacin33.30
Cotrimoxazole50100
Erythromycin41.7100
Gentamicin33.3100
Methicillin33.3NT
Vancomycin00

*NT: not tested.

ESBL production was confirmed in 35 (25%) isolates and the majority consisted of Pseudomonas spp. with 15 (42.8%) followed by K. pneumoniae with 12 (34.3%). Out of the 51 (37.2%) AmpC β-lactamase-positive isolates, Acinetobacter spp. were the most frequent ones with 22 (41.5%) followed by K. pneumoniae with 13 (24.5%). MBL production was confirmed in 11 (36.7%) bacterial isolates and among them, 6 (54.5%) isolates were Acinetobacter spp. followed by K. pneumoniae and Pseudomonas spp., each with 2 (18.2%) and a single isolate of K. oxytoca (9.1%). The results are shown in Table 4.
Table 4

Profile of β-lactamase-producing bacterial strains from tracheal aspirate of ICU patients.

OrganismsESBL producers (no. and %)AmpC β-lactamase producers (no. and %)MBL producers (no. and %)
Acinetobacter spp.5 (14.3)22 (43.1)6 (54.5)
K. pneumoniae 12 (34.3)13 (24.5)2 (18.2)
Pseudomonas spp.15 (42.8)9 (17.6)2 (18.2)
E. coli 3 (8.6)4 (7.8)0
Enterobacter spp.02 (4)0
K. oxytoca 01 (2)1 (9.1)
C. freundii 000
P. vulgaris 000
S. aureus 000
S. pneumoniae 000
Total 35 (25) 51 (37.2) 11 (36.7)

4. Discussion

The results of the study showed high growth rate, which was in accordance with the previous study, which reported culture positivity of 90% [13]. Polymicrobial growth was observed in one-tenth of the cases and the growth of multiple organisms from tracheal specimen has been mentioned in similar studies [14, 15]. The colonization of the oropharynx, aspiration of the contaminated secretions into the lower airway, mechanical ventilation, and endotracheal tube biofilm play important role as reservoirs for infecting microorganisms [15]. In the present study, 85.4% of Acinetobacter spp., the most predominant isolate of tracheal aspirate, were MDR-strains. High level of resistance by Acinetobacter spp. was shown against cotrimoxazole (96.4%), cefotaxime (87.3%), ciprofloxacin (80%), and amikacin (78.2%). Similar trends in antimicrobial resistance (85% to ceftazidime and ciprofloxacin, 82% to cotrimoxazole, and 67% to amikacin) of Acinetobacter spp. have been observed [16]. Acinetobacter species possess a wide array of β-lactamases that hydrolyze and confer resistance to penicillins, cephalosporins, and carbapenems. The other mechanisms of resistance include loss of porin proteins and presence of multiple efflux pumps that remove wide range of antibiotics out of the bacterial cell [17]. In this study, 73.8% of K. pneumoniae were MDR-strains. These isolates showed high level of resistance against cotrimoxazole (85.7%), cefotaxime (78.6%), gentamicin (69%), and ciprofloxacin (64.3%), which was in harmony with the previous study that reported resistance of 63.1% to cotrimoxazole, 90.5% to cefotaxime, 89% to gentamicin, and 65.8% to ciprofloxacin [18]. High level of drug resistance seen among K. pneumoniae is mediated by the production of various types of β-lactamases primarily ESBL, AmpC, and metallo-β-lactamases along with drug efflux [19]. In the present study, 51.3% of Pseudomonas spp. were MDR-strains. Pseudomonas spp. were resistant to cotrimoxazole (86%), cefotaxime (83.8%), ciprofloxacin (51.4%), and gentamicin (43.2%) which was comparable to the results of two studies [18, 20]. Pseudomonas spp. display an elevated level of drug resistance mechanisms that include production of different types of β-lactamases primarily ESBL, AmpC enzymes, and metallo-carbapenemases, aminoglycoside-modifying enzymes, loss of porin proteins, and the presence of efflux pumps like MexAB-Opr M [17]. ESBL production was confirmed in 35 (25%) screen-positive isolates and the highest number of ESBL production was detected in Pseudomonas spp. (42.8%) followed by K. pneumoniae (34.3%), which was in contrary to one of the studies conducted in Nepal that showed higher prevalence of E. coli with 80% and K. pneumoniae with 57.1% [21]. Higher rate of ESBL production in P. aeruginosa has now been increasingly reported due to predominantly occurring SHV- and OXA-type ESBLs [7]. AmpC β-lactamase was confirmed in 51 (37.2%) of the screen-positive isolates and Acinetobacter spp. constituted 22 (43.1%) followed by K. pneumoniae with 13 (25.5%). Plasmidic AmpC genes are derived from the chromosomal AmpC genes of Enterobacter cloacae, Citrobacter freundii, Morganella morganii, and Hafnia alvei. Most plasmid-mediated AmpC β-lactamases are constitutively expressed, but some enzymes, such as DHA-1, DHA-2, ACT-1, CFE-1, and CMY-13, are inducible and may be more clinically dangerous conferring the capability for an organism to become more resistant during β-lactam therapy [22]. In this study, phenylboronic acid was used as an inhibitor of AmpC β-lactamase and high sensitivity and specificity of 90% and 98.2%, respectively, for this method have been reported [11]. MBL production was confirmed in 11 (36.7%) of the screen-positive isolates that constitute 54.5% of Acinetobacter spp., K. pneumoniae, and Pseudomonas spp., each with 18.2% and 9.1% of K. oxytoca. In contrast with this finding, a Korean study reported MBL production in only 14.2% of A. baumannii and 11.4% of P. aeruginosa [23]. The most common transferable MBL families include the VIM-, IMP-, GIM-, SPM-, and SIM-type enzymes, which have been detected primarily in P. aeruginosa but are also found in other Gram-negative bacteria, including nonfermenters and members of the family Enterobacteriaceae [24]. MBL-producing bacteria are an increasing public health problem worldwide and mortality rates have been increased due to inadequate empirical therapy [25]. In the present study, MBL production was detected using Imipenem-EDTA combined disk method, which has sensitivity and specificity of 100% and 98%, respectively [26].

5. Conclusion

We conclude that Gram-negative bacilli were the predominant isolates of tracheal aspirate of ICU patients. There is a high rate of resistance to cephalosporins, fluoroquinolones, aminoglycosides, and cotrimoxazole. β-lactamases confer a high level of resistance to β-lactam antibiotics and these traits are usually carried in transferable genes, which are capable of being acquired by normally nonpathogenic bacteria. Therefore, early detection in routine laboratory, immediate infection control, and antibiotic stewardship programs should be implemented in order to limit the spread of β-lactamase-producing organisms.
  22 in total

1.  In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli.

Authors:  Carl Urban; Noriel Mariano; James J Rahal
Journal:  Antimicrob Agents Chemother       Date:  2010-04-05       Impact factor: 5.191

Review 2.  Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa.

Authors:  Robert A Bonomo; Dora Szabo
Journal:  Clin Infect Dis       Date:  2006-09-01       Impact factor: 9.079

Review 3.  The epidemiology and control of Acinetobacter baumannii in health care facilities.

Authors:  Pierre Edouard Fournier; Hervé Richet
Journal:  Clin Infect Dis       Date:  2006-01-26       Impact factor: 9.079

4.  Antimicrobial resistance pattern among aerobic gram-negative bacilli of lower respiratory tract specimens of intensive care unit patients in a neurocentre.

Authors:  H B Veena Kumari; S Nagarathna; A Chandramuki
Journal:  Indian J Chest Dis Allied Sci       Date:  2007 Jan-Mar

Review 5.  Ventilator-associated pneumonia.

Authors:  Jean Chastre; Jean-Yves Fagon
Journal:  Am J Respir Crit Care Med       Date:  2002-04-01       Impact factor: 21.405

Review 6.  Extended-spectrum beta-lactamases: a clinical update.

Authors:  David L Paterson; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

Review 7.  Ventilator-associated pneumonia in neonatal and pediatric intensive care unit patients.

Authors:  Elizabeth Foglia; Mary Dawn Meier; Alexis Elward
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

8.  Metallo-beta-lactamase detection: comparative evaluation of double-disk synergy versus combined disk tests for IMP-, GIM-, SIM-, SPM-, or VIM-producing isolates.

Authors:  Renata C Picão; Soraya S Andrade; Adriana Gianinni Nicoletti; Eloiza H Campana; Gabriela C Moraes; Rodrigo E Mendes; Ana C Gales
Journal:  J Clin Microbiol       Date:  2008-03-05       Impact factor: 5.948

9.  Nosocomial tracheobronchitis in mechanically ventilated patients: incidence, aetiology and outcome.

Authors:  S Nseir; C Di Pompeo; P Pronnier; S Beague; T Onimus; F Saulnier; B Grandbastien; D Mathieu; M Delvallez-Roussel; A Durocher
Journal:  Eur Respir J       Date:  2002-12       Impact factor: 16.671

10.  VIM- and IMP-type metallo-beta-lactamase-producing Pseudomonas spp. and Acinetobacter spp. in Korean hospitals.

Authors:  Kyungwon Lee; Wee Gyo Lee; Young Uh; Gyoung Yim Ha; Jihyun Cho; Yunsop Chong
Journal:  Emerg Infect Dis       Date:  2003-07       Impact factor: 6.883

View more
  16 in total

1.  Community acquired multi-drug resistant clinical isolates of Escherichia coli in a tertiary care center of Nepal.

Authors:  Shamshul Ansari; Hari Prasad Nepal; Rajendra Gautam; Sony Shrestha; Puja Neopane; Ganga Gurung; Moti Lal Chapagain
Journal:  Antimicrob Resist Infect Control       Date:  2015-05-01       Impact factor: 4.887

2.  Incidence of metallo-beta-lactamase producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in central Nepal.

Authors:  Arijit Bora; Rajkumari Sanjana; Brajesh Kumar Jha; Surya Narayan Mahaseth; Khilasa Pokharel
Journal:  BMC Res Notes       Date:  2014-08-21

3.  Review on the Antimicrobial Resistance of Pathogens from Tracheal and Endotracheal Aspirates of Patients with Clinical Manifestations of Pneumonia in Bacolod City in 2013.

Authors:  Alain C Juayang; Dominador G Maestral; Gemma B de Los Reyes; Michael Angelo D Acosido; Christine T Gallega
Journal:  Int J Bacteriol       Date:  2015-02-03

4.  Growing Menace of Antibacterial Resistance in Clinical Isolates of Pseudomonas aeruginosa in Nepal: An Insight of Beta-Lactamase Production.

Authors:  Shamshul Ansari; Rabindra Dhital; Sony Shrestha; Sangita Thapa; Ram Puri; Niraj Chaudhary; Suresh Khatiwada; Rajendra Gautam
Journal:  Biomed Res Int       Date:  2016-08-23       Impact factor: 3.411

5.  Incidence of Multidrug-Resistant Pseudomonas Spp. in ICU Patients with Special Reference to ESBL, AMPC, MBL and Biofilm Production.

Authors:  Richa Gupta; Abida Malik; Meher Rizvi; S Moied Ahmed
Journal:  J Glob Infect Dis       Date:  2016 Jan-Mar

6.  Presence of metallo-beta-lactamases (MBL), extended-spectrum beta-lactamase (ESBL) & AmpC positive non-fermenting Gram-negative bacilli among Intensive Care Unit patients with special reference to molecular detection of blaCTX-M & blaAmpC genes.

Authors:  Richa Gupta; Abida Malik; Meher Rizvi; Moied Ahmed
Journal:  Indian J Med Res       Date:  2016-08       Impact factor: 2.375

7.  A hospital based surveillance of metallo-beta-lactamase producing gram negative bacteria in Nepal by imipenem-EDTA disk method.

Authors:  Pratigya Thapa; Dinesh Bhandari; Dhiraj Shrestha; Hiramani Parajuli; Prakash Chaudhary; Jyoti Amatya; Ritu Amatya
Journal:  BMC Res Notes       Date:  2017-07-25

8.  Biofilm Formation by Pathogens Causing Ventilator-Associated Pneumonia at Intensive Care Units in a Tertiary Care Hospital: An Armor for Refuge.

Authors:  Sujata Baidya; Sangita Sharma; Shyam Kumar Mishra; Hari Prasad Kattel; Keshab Parajuli; Jeevan Bahadur Sherchand
Journal:  Biomed Res Int       Date:  2021-05-28       Impact factor: 3.411

9.  Nosocomial Isolates and Their Drug Resistant Pattern in ICU Patients at National Institute of Neurological and Allied Sciences, Nepal.

Authors:  Pashupati Bhandari; Ganesh Thapa; Bharat Mani Pokhrel; Dwij Raj Bhatta; Upendra Devkota
Journal:  Int J Microbiol       Date:  2015-10-26

10.  A descriptive study of nosocomial infections in an adult intensive care unit in fiji: 2011-12.

Authors:  Keshni Naidu; Ilisapeci Nabose; Sharan Ram; Kerri Viney; Stephen M Graham; Karen Bissell
Journal:  J Trop Med       Date:  2014-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.